cyclin-dependent kinase

(redirected from Cyclin dependent kinase)
Also found in: Acronyms, Encyclopedia.

cyclin-dependent kinase (CDK)

a protein kinase that is activated by cyclin.

cyclin-dependent kinase

Abbreviation: CDK
A family of enzymes involved in regulation of the cell cycle. They serve as targets for pharmacological manipulation of this cycle, particularly during the unregulated proliferation of tumor cells.
See also: kinase
References in periodicals archive ?
One group of these novel compounds works by inhibiting Cyclin Dependent Kinases (CDK), drug targets that control cancer cell division.
United States Patent 6,531,479 relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like.
Seliciclib is an orally available cyclin dependent kinase (CDK) inhibitor that selectively inhibits multiple enzyme targets that are central to the process of cell division and cell cycle control.
Cyclin Dependent Kinase (CDK) Inhibitor CYC202 Ameliorates Experimental Crescentic Glomerulonephritis.
Abstract Number: 154 A Phase I and Pharmacokinetic (PK) Trial of CYC202, a Novel Oral Cyclin Dependent Kinase (CDK) inhibitor, in Patients with Advanced Solid Tumors.
This data suggests that combination therapy where a Cyclin Dependent Kinase inhibitor is used along with selected standard chemotherapies may provide a new therapeutic option in the treatment of cancer.
Mitotix has formed major collaborations in cancer therapeutics with The DuPont Pharmaceuticals Company focused on cyclin dependent kinase inhibitors and with BASF Pharma focused on cdc25 inhibitors.
5,866,702 entitled, "Purine Inhibitors of Cyclin Dependent Kinase 2," encompasses molecules which are potent and selective inhibitors of the enzyme CDK2, a critical regulatory protein which participates in the control of the cell cycle.
Anti-Cancer Compounds: The invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like.
As an extremely promising new class of enzyme targets, the cyclin dependent kinases have precisely defined roles in the cell division process, and are altered in many cancers," said Paul Friedman, President, Research and Development, DuPont Merck.